GoAI
Get started
Kingworld Medicines Group Limited logo

Kingworld Medicines Group Limited

1110.HK

HKSEHealthcareMedical - Distribution

Open in GoAI

Latest quote

HK$0.46

HK$0.00 · 0.00%

Aug 24, 11:02 AM HKT

1110.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Li Sheng Zhao
Listed since
Nov 25, 2010
Employees
732

Market position

Day range

Current HK$0.46

52-week range

Current HK$0.46

Open
HK$0.465
Previous close
HK$0.46
Volume
452K
0.26× average
Average volume
1.76M
Average daily volume
Market cap
271.31M HKD
Beta
0.85
Market reference 1
50-day average
HK$0.4236
+8.59% above average
200-day average
HK$0.4821
-4.57% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
443.31M CNY
P/E (TTM)
21.31×
P/B (TTM)
0.38×
P/S (TTM)
0.25×
EV / EBITDA
6.15×
Earnings yield
4.12%
Free cash flow yield
20.06%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
27.02%
Operating margin
6.89%
Net margin
1.23%
Return on equity
1.83%
Return on assets
0.78%
Return on invested capital
3.72%

Financial health

Debt / equity
0.7×
Current ratio
1.09×
Altman Z-score
2.38
Piotroski F-score
6 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends34%22%10%-2%Gross margin, FY2021: 31.11%Gross margin, FY2022: 28.99%Gross margin, FY2023: 26.02%Gross margin, FY2024: 25.49%Gross margin, FY2025: 27.02%Operating margin, FY2021: 8.52%Operating margin, FY2022: 7.54%Operating margin, FY2023: 8.97%Operating margin, FY2024: 8.45%Operating margin, FY2025: 6.89%Net margin, FY2021: 3.58%Net margin, FY2022: 2.37%Net margin, FY2023: 3.53%Net margin, FY2024: 3.92%Net margin, FY2025: 1.23%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 31.11%. Gross margin FY2022 28.99%. Gross margin FY2023 26.02%. Gross margin FY2024 25.49%. Gross margin FY2025 27.02%. Operating margin FY2021 8.52%. Operating margin FY2022 7.54%. Operating margin FY2023 8.97%. Operating margin FY2024 8.45%. Operating margin FY2025 6.89%. Net margin FY2021 3.58%. Net margin FY2022 2.37%. Net margin FY2023 3.53%. Net margin FY2024 3.92%. Net margin FY2025 1.23%.

Income trends

Revenue

917.34M CNY-13.55%

Operating income

63.16M CNY-29.59%

Net income

11.28M CNY-72.85%
Income trends across reported periods1.19B CNY758.45M CNY331.5M CNY−95.46M CNYRevenue, FY2021: 847.39M CNYRevenue, FY2022: 957.7M CNYRevenue, FY2023: 1.08B CNYRevenue, FY2024: 1.06B CNYRevenue, FY2025: 917.34M CNYOperating income, FY2021: 72.23M CNYOperating income, FY2022: 72.24M CNYOperating income, FY2023: 96.81M CNYOperating income, FY2024: 89.7M CNYOperating income, FY2025: 63.16M CNYNet income, FY2021: 30.32M CNYNet income, FY2022: 22.74M CNYNet income, FY2023: 38.1M CNYNet income, FY2024: 41.56M CNYNet income, FY2025: 11.28M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 847.39M CNY. Revenue FY2022 957.7M CNY. Revenue FY2023 1.08B CNY. Revenue FY2024 1.06B CNY. Revenue FY2025 917.34M CNY. Operating income FY2021 72.23M CNY. Operating income FY2022 72.24M CNY. Operating income FY2023 96.81M CNY. Operating income FY2024 89.7M CNY. Operating income FY2025 63.16M CNY. Net income FY2021 30.32M CNY. Net income FY2022 22.74M CNY. Net income FY2023 38.1M CNY. Net income FY2024 41.56M CNY. Net income FY2025 11.28M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue917.34M CNY1.06B CNY1.08B CNY957.7M CNY847.39M CNY
Cost of goods sold669.44M CNY790.64M CNY797.99M CNY680.07M CNY583.79M CNY
Gross profit247.91M CNY270.45M CNY280.67M CNY277.63M CNY263.6M CNY
Research and development21.8M CNY17.59M CNY18.84M CNY15.52M CNY13.41M CNY
Selling, general, and administrative176.99M CNY189.5M CNY222.29M CNY205.03M CNY196.16M CNY
Operating expenses184.74M CNY180.74M CNY183.86M CNY205.39M CNY191.37M CNY
Interest income4.72M CNY6.27M CNY2.4M CNY1.46M CNY1.19M CNY
Interest expense14.05M CNY13.28M CNY11.52M CNY12.29M CNY11.78M CNY
Depreciation and amortization15.33M CNY9.84M CNY20.08M CNY38.19M CNY34.78M CNY
Operating income63.16M CNY89.7M CNY96.81M CNY72.24M CNY72.23M CNY
Net income11.28M CNY41.56M CNY38.1M CNY22.74M CNY30.32M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.02

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.110.060.01-0.04Q2 '21Q4 '21Q3 '22Q2 '23Q2 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual 0.039, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 0.022, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 31, 2022: actual 0.047, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 22, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 30, 2023: actual 0.069, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 0.001, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 0.056, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 0.021, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.22B956.12M696.87M437.63MQ2 '21No estimateQ4 '21No estimateQ3 '22No estimateQ2 '23MissQ2 '23No estimateQ1 '24MissQ3 '24No estimateQ1 '25No estimate
Q2 2021, reported Jun 30, 2021: actual 498.62M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 529.03M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 31, 2022: actual 491.26M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Apr 22, 2023: actual 612.8M HKD, estimate 1.16B HKD, surprise -47.25%, Miss. Q2 2023, reported Jun 30, 2023: actual 598.04M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 581.78M HKD, estimate 1.16B HKD, surprise -49.92%, Miss. Q3 2024, reported Aug 29, 2024: actual 564.97M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 569.13M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.0317

2025 complete year+387.7% since 2021

Corporate action history

Dividend

Ex-dividend Jun 5, 2025

HK$0.0317

Annual

Record Jun 6, 2025 · Payment Jun 30, 2025

Dividend

Ex-dividend Jun 3, 2024

HK$0.0338

Annual

Record Jun 4, 2024 · Payment Jun 28, 2024

Dividend

Ex-dividend Jun 1, 2023

HK$0.0247

Annual

Record Jun 2, 2023 · Payment Jun 30, 2023

Dividend

Ex-dividend May 31, 2022

HK$0.0239

Annual

Record Jun 1, 2022 · Payment Jun 30, 2022

Dividend

Ex-dividend Jun 1, 2021

HK$0.0065

Annual

Record Jun 2, 2021 · Payment Jun 30, 2021

Dividend

Ex-dividend Jun 1, 2020

HK$0.0234

Annual

Record Jun 2, 2020 · Payment Jun 29, 2020

1110.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$195.4

-5.05%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

-3.53%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$220.2

-3.42%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.30

-5.29%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$98.90

-3.42%

Continue in GoAI

Research 1110.HK

research.disclaimer